Expression of c-MET in Invasive Meningioma

• DOI: 10.4132/jptm.2014.10.13
• Publication Date: 2015-01-16T01:32:27Z
• Authors: Sumi Yun; Jae Moon Koh; Kyu Sang Lee; An Na Seo; Kyung Han Nam; Gheeyoung Choe
• Keywords: Hepatocyte growth factor; 03 medical and health sciences; 0302 clinical medicine; Neoplasm invasiveness; Pathology; RB1-214; Original Article; Meningioma; Immunohistochemistry; Proto-oncogene proteins c-MET; 3. Good health

Meningiomas show high recurrence rates even after curative tumor removal. The invasiveness of meningiomas may contribute to their high recurrence rates. Recently, c-MET and hepatocyte growth factor (HGF) have been reported to be involved in cancer invasion.We examined the immunohistochemical expression of c-MET and HGF in 100 cases of patients with meningiomas who have undergone complete tumor removal.c-MET(-High) and HGFHigh were found in 17% and 13% of meningiomas, respectively. Brain invasion was observed in 17.6% of c-MET(-High) meningiomas, but in only 2.4% of c-MET(-Low) meningiomas (p=.033). Bone/soft tissue invasion was observed in 23.5% of c-MET(-High) meningiomas and in 9.6% of c-MET(-Low) meningiomas (p=.119). HGF(-High) did not show statistical association with brain invasion or bone/soft tissue invasion. c-MET(-High) demonstrated shorter recurrence-free survival (RFS, 93.5±8.2 months vs 96.1±1.9 months); however, this difference was not statistically significant (p=.139). There was no association of HGF(-High) with RFS.This study demonstrates that c- MET(-High) is associated with brain invasion of meningiomas, and that c-MET expression may be a useful predictive marker for meningioma recurrence. Patients with invasive meningiomas with high expressions of c-MET may be good candidates for targeted therapy using c-MET inhibitors.